Citation Impact
Citing Papers
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease
2022
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
2006
Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
2014
A Meta-Analysis of Cytokines in Major Depression
2009 Standout
Medication Augmentation after the Failure of SSRIs for Depression
2006 Standout
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2006 Standout
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
2021
Depression
2018 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
2006 Standout
Augmentation of Antidepressants with Atypical Antipsychotics: A Review of the Current Literature
2008
Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study
2003
Switching to bupropion in fluoxetine-resistant major depressive disorder.
2003
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
Inflammation and Alzheimer's disease
2000 Standout
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
2007
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
2007 Standout
Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein
2003
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains
2001 Standout
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
2012 Standout
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
2009
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
2008 Standout
Schizophrenia
2009 Standout
Long-Acting Risperidone
2004
Alzheimer's disease
2011 Standout
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice
2006 Standout
Mild Cognitive Impairment
2011 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment
2005 Standout
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
2008
CSF markers for incipient Alzheimer's disease
2003
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
2003
IL-6 as a keystone cytokine in health and disease
2015 Standout
Structural and functional features of central nervous system lymphatic vessels
2015 StandoutNature
Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer’s disease
2002
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
2007
Depression and Quality of Life in Older Persons: A Review
2015 Standout
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
2009 Standout
A Meta-Analysis of Cytokines in Alzheimer's Disease
2010
Rethinking schizophrenia
2010 StandoutNature
Alzheimer's disease
2006 Standout
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
2006 Standout
Current Concepts in Mild Cognitive Impairment
2001 Standout
Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
2000
Post-translational modifications of tau protein in Alzheimer’s disease
2004
Appropriate prescribing in elderly people: how well can it be measured and optimised?
2007 Standout
Alzheimer's Disease
2010 Standout
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
2007
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
2021
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
2003 Standout
The Pathobiology of Vascular Dementia
2013 Standout
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the Twenty-Seventh Annual Meeting of the Society for Neuroscience, October 25–30, 1997, New Orleans, LA, USA.1
1999
If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans.
2007 Standout
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Plasma and Cerebrospinal Fluid Interleukin-6 Concentrations in Posttraumatic Stress Disorder
2001
Mild cognitive impairment as a diagnostic entity
2004 Standout
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
2008 Standout
Inappropriate Medications for Elderly Patients
2004
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
Lecanemab in Early Alzheimer’s Disease
2022 Standout
Relationships between biomarkers in aging and dementia
2009
The EPPIC Follow-Up Study of First-Episode Psychosis
2010
INFLAMMATION AND ALZHEIMERS DISEASE
2000
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)
2006 Standout
The effectiveness of the treatment of depression in the physically ill elderly
2000
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
2001
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
2007 StandoutScience
Mild Cognitive Impairment
2016
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot
2012
Works of Robert Lasser being referenced
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
2017
A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder
2006
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation
2006
Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy
1997
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
2005
Longitudinal stability of CSF tau levels in Alzheimer patients
1999
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
Discriminant power of combined cerebrospinal fluid τ protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1
1999
Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130
1999
Newer Psychotropic Medication Use in Nursing Home Residents
1998
Diagnosis and Treatment of Geriatric Depression
1998
Patient-based and clinician-based support for the remission criteria in schizophrenia.
2007
Long-acting risperidone: Prolonged-release injectable delivery of risperidone using medisorbò microsphere technology
2003